Maybe because it isn't vla?
Three trials with Keytrunda Melanoma and Sydney:
https://www.clinicaltrials.gov/ct2/results?term=keytruda sydney melanoma
Keytrunda is in (or has planned) 606 different trials overall:
https://www.clinicaltrials.gov/ct2/...recrs=a&age_v=&gndr=&type=&rslt=&Search=Apply
On another note I was thinking about a counter offer.
Sirtex attracted one, but then that's making money.
Perhaps the only possible counter bidder for vla is BristolMS, as they are the only other company than Merck to have some data with their own drug. But would BMS really want to do a big pharma bidding war with Merck for vla? vla is not a must have for BMS, if it was they would have snapped us up long ago.
